Tezepelumab in Canadian Adults With Severe Chronic Rhinosinusitis With Nasal Polyps: A Subgroup Analysis of the Phase 3 WAYPOINT Trial.

What was studied

This study looked at tezepelumab for severe nasal polyps with long-term sinus swelling. The people were adults in Canada whose illness was not under control. They were part of a larger phase 3 trial called WAYPOINT. Chance decided who got the drug and who got a dummy drug. 25 people got tezepelumab 210 mg, and 24 got the dummy drug. Shots under the skin were given every 4 weeks for 52 weeks. The team looked back at this group from Canada after the trial.

What they found

The group from Canada had more people with asthma than the whole trial. It also had more people whose breathing got worse with some pain drugs. With tezepelumab, polyp size seen with a scope got smaller than with the dummy drug. People on the drug also said their blocked nose felt better. The gain was about the same as in the whole trial. Fewer people on the drug needed rescue care, such as polyp surgery or steroids. No one in this group had a serious side effect. No one stopped the drug due to side effects.

What it means for patients

The authors say tezepelumab works and is safe for this severe illness. They say this group looks like the patients seen in clinics in Canada. So they feel the main trial results also apply to care in Canada.

Why it is not certain yet

Only 25 people got the drug and 24 got the dummy drug. The team chose to look at this group after the trial was done. Such looks back at part of a trial can find chance results. The abstract does not say what happened after 52 weeks.

Source

Tezepelumab in Canadian Adults With Severe Chronic Rhinosinusitis With Nasal Polyps: A Subgroup Analysis of the Phase 3 WAYPOINT Trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.